ArticleCommunications biology2026
African swine fever virus-encoded protein MGF 505-3R impairs innate immunity via ubiquitin-mediated degradation of MyD88.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploiting Ubiquitination: African Swine Fever Virus-Mediated Recruitment of Host E3 Ligases During Viral Infection and Immune Regulation.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a highly contagious viral disease caused by the African swine fever virus (ASFV), which primarily affects pigs. ASFV encodes a variety of proteins that contribute to immune evasion, with the mechanisms of immune escape being diverse, complex, and not yet fully understood. In this study, the MGF 505-3R protein of ASFV was identified as a potential inhibitor of the host's inflammatory response. We demonstrate that MGF 505-3R suppresses the host antiviral response by promoting the ubiquitin-mediated degradation of MyD88, with the amino acid region 89-277 being essential for this function. Notably, this region directly mediates the interaction with MyD88 and induces its ubiquitination. Furthermore, MGF 505-3R and its derived peptide significantly inhibit the production of type I (IFN-α/β) and type III (IFN-λ) interferons, in addition to impairing NF-κB activation by blocking p65 phosphorylation and nuclear translocation. The MGF 505-3R peptide effectively attenuates the host inflammatory storm, decreasing the expression of cytokines such as TNF-α and IL-1β, and alleviating DSS-induced colitis in male C57BL/6 mice. These findings highlight the dual role of MGF 505-3R in suppressing both inflammatory and interferon pathways, underscoring its potential as a therapeutic candidate for inflammatory diseases and a target for antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.